$4.38
Open on report
$1.55
Close on report
-64.61%
% since report
CDIO — Fugazi Research · Activ8 Insights
A Heartbreaking
Activ8 Insights — Short Research Dashboard
Source: Fugazi Research
Published March 13, 2026
▼ Short Position
NASDAQ: CDIO
Cardiovascular Diagnostics
Fugazi Research · Mar 13, 2026
A Heartbreaking
Diagnosis for Investors
Near-zero revenue, relentless dilution, and a de-SPAC structure that raises serious questions about who Cardio Diagnostics was ever built to serve.
"The company lost more than $445 to generate $1 of revenue."
Fugazi Research — nine months ended September 30, 2025
Lifetime Revenue
~$65K
Since inception through 9M 2025
9M 2025 Revenue
$11,270
−63% vs. prior year period
Net Margin (9M 2025)
−44,500%
$5.03M loss on $11.3K revenue
Accumulated Deficit
$27.8M
Several times the market cap
Float Expansion
+476%
Since de-SPAC · Oct 2022
Dilution vs. Revenue
309×
$3.5M raised vs $11.3K earned (9M 2025)
ATM Overhang
$5.86M
~65% of approx. $9M market cap
Activ8 Insights — Evaluation Framework
Reports scored across three independent dimensions: thesis gravity, evidence quality, and catalyst specificity. Scores determine language register and design treatment throughout this dashboard.
Report Score
A2 / B2 / C2
Governance and mismanagement thesis — supported by documentary evidence (SEC filings, court records, corporate registry) — with soft catalysts but no explicit price target. Language is measured throughout: "raises serious questions," "warrants scrutiny."
A
Thesis Strength
HIGH
A3 — Fraud / Deception
Accounting fraud, deliberate misrepresentation, knowing concealment
MED
A2 — Governance / Mismanagement
Conflicts of interest, self-dealing, reckless oversight of investor capital
LOW
A1 — Structural / Valuation
Overpricing, business erosion, macro-driven concerns
B
Evidence Quality
HIGH
B3 — Primary Investigation
FOIA requests, original interviews, site visits, proprietary data
MED
B2 — Documentary
SEC filings, court records, regulatory documents, corporate registry filings
LOW
B1 — Analytical
Financial analysis, peer comps, pattern-based inference from public data
C
Catalyst & Downside
HIGH
C3 — Hard Catalyst
Datable event with sized downside and explicit price target
MED
C2 — Soft Catalyst
Probable but undated — ATM dilution, listing fragility, cash runway pressure
LOW
C1 — Thesis-Only
No clear trigger; long-duration short with no specific event
Active Score:
A2 — Governance / Mismanagement
B2 — Documentary Evidence
C2 — Soft Catalyst
Investment Thesis
Cardio Diagnostics (CDIO) warrants serious scrutiny as a de-SPAC whose structure appears to have been engineered to benefit its architects at the expense of public investors.
The company went public in October 2022 through a blank-check merger after its SPAC sponsor cycled through more than 20 failed candidates, ultimately selecting a company that had generated $901 in total lifetime revenue. At the center of the transaction is a dual conflict: the SPAC's CEO simultaneously served as managing director at its own underwriter. A concealed second player, Tong Mao — a Hong Kong-based specialist in structuring Chinese capital into U.S. markets — transferred 1.56 million shares and 2.5 million warrants to unidentified recipients on the day after closing, with no beneficial ownership successor ever filing with the SEC. Since going public, CDIO has raised more than $15 million through equity sales while generating only approximately $65,000 in cumulative revenue, has executed a 1-for-30 reverse stock split to avoid Nasdaq delisting, and maintains an ATM facility with capacity equal to roughly 65% of its market capitalization. Fugazi Research considers the shares completely uninvestable.
Core Allegations
🏗️
Serial Sponsor, Structural Conflict
Jonathan Intrater served simultaneously as CEO of MAAQ and managing director of its underwriter Ladenburg Thalmann — a dual role explicitly disclosed as a conflict. His two prior de-SPACs have combined to destroy approximately 99% of investor capital. He was also previously named a defendant in a civil fraud lawsuit related to a private placement, though the case was ultimately dismissed on damages grounds.
Governance
🕵️
Opaque Post-Closing Share Transfer
The day after the de-SPAC closed, Mana Capital LLC transferred 1.565 million shares and 2.5 million warrants to Juventus LLC and other unidentified recipients at zero consideration. No successor beneficial ownership report has been filed with the SEC since. Fugazi characterizes this absence not as administrative oversight, but as a premeditated structural choice that leaves the ultimate beneficiaries unknown.
Regulatory
📉
Near-Zero Commercial Revenue
CDIO generated just $901 before going public, and approximately $65,000 in cumulative revenue across its entire operational history since inception. Revenue for the nine months ended September 30, 2025 totaled $11,270 — less than the company spent on office and computer equipment ($29,264) during the same period. Revenue also fell 63% year-over-year following the loss of a single customer.
Financial
🔄
Dilution as De Facto Business Model
CDIO has expanded its float by 476% since the de-SPAC and executed a 1-for-30 reverse stock split solely to regain Nasdaq minimum bid price compliance. The company's at-the-market facility retains approximately $5.86 million in remaining capacity — equivalent to roughly 65% of its market capitalization — representing a substantial ongoing dilution overhang for current shareholders.
Financial
📢
AI Narrative Untethered from Reality
Management promotes Epi+Gen CHD and PrecisionCHD as AI-powered precision cardiovascular diagnostics with access to a vast global market. The operating results tell a different story: a few thousand dollars of revenue per quarter against multi-million dollar losses. A February 2026 investor conference call — containing no revenue guidance and no new financial disclosures — nonetheless drove a 450% share price increase in eight consecutive trading days.
Governance
⚠️
Structural Fragility & Listing Risk
With $27.8 million in accumulated deficit, a monthly cash burn of approximately $484,000, and only roughly 13 months of estimated runway, Fugazi assesses CDIO as currently in Phase 5 of a classic microcap death spiral — past the promotional peak and entering downward acceleration. Prior Nasdaq deficiency notices and the reverse split signal continued listing vulnerability.
Financial
Key Financial Data
Revenue Collapse: Nine-Month Comparison
Source: CDIO Form 10-Q, September 30, 2025 · January–September periods compared · Decline attributed to loss of single customer, Family Medicine Specialists
9 Months 2024
$30,400
9 Months 2025
$11,270
−63% year-over-year
What the Capital Actually Funds
Source: CDIO Form 10-Q, September 30, 2025 · CEO annual base salary for context · All figures sourced directly from the report
CEO Annual Base Salary
$300,000
~26.6× total 9M revenue
Office & Computer Equipment (9M)
$29,264
Exceeds total 9M revenue
Total Revenue (9M 2025)
$11,270
Chronology of Concern
Mar 2021
Juventus LLC Incorporated — Before the SPAC Exists
Tong Mao's shell vehicle registered in Delaware, two months before Mana Capital Acquisition Corp is even formed. Fugazi characterizes this as evidence of a pre-engineered structure.
May 2021
Mana Capital Acquisition Corp (MAAQ) Formed
Blank check company established with Jonathan Intrater as sole officer and CEO — simultaneously serving as managing director at Ladenburg Thalmann, which acts as SPAC underwriter. A conflict of interest explicitly disclosed in the S-4.
Apr 2022
20+ Failed Candidates — Cardio Diagnostics Selected as Last Resort
MAAQ reviews more than 20 targets spanning pharma, beverages, EVs, and real estate. Intrater is first contacted about Cardio on April 8; a preliminary agreement is reached nine days later. At that moment, Cardio Diagnostics has generated $901 in total lifetime revenue.
Oct 2022
De-SPAC Closes — CDIO Enters Nasdaq
The merger closes, bringing Cardio Diagnostics to public markets. Mana Capital LLC and Juventus LLC together hold 1.62 million founder shares acquired for $25,000 — approximately $0.015 per share.
Oct 26, 2022
Shares Transferred to Unidentified Recipients — Day After Closing
Mana Capital LLC transfers 1.565 million shares and 2.5 million warrants to Juventus LLC and other unidentified parties at zero consideration. This is Tong Mao's only appearance in CDIO's SEC filing history. No identifiable successor files a beneficial ownership report from that date forward.
Jun 2024
Nasdaq Minimum Bid Deficiency Notice
Nasdaq notifies CDIO that its share price has been below $1.00 for 30 consecutive business days. A 180-day compliance extension is granted in December 2024, with delisting as the alternative.
Jun 2025
1-for-30 Reverse Stock Split Executed
Implemented solely to regain Nasdaq bid price compliance. No value is created; shares are consolidated from roughly 50 million to approximately 1.66 million post-split. The dilution cycle is expected to continue through the ATM facility.
Feb 19, 2026
Investor Conference Call Drives 450% Price Surge
A live investor call filed via 8-K contains no revenue guidance, no financial projections, and no new commercial disclosures. The share price rises from $1.19 to $6.55 in eight consecutive trading days — a 450% increase attributed by Fugazi to low-float momentum dynamics rather than any change in business fundamentals.
Mar 13, 2026
Fugazi Research Report Published
Fugazi characterizes CDIO as "completely uninvestable and of Zero value," placing it in Phase 5 of a microcap death spiral — past the promotional peak and entering downward acceleration.
Company Profile
Full Name
Cardio Diagnostics Holdings, Inc.
Ticker / Exchange
CDIO · Nasdaq
Sector
Cardiovascular Diagnostics (AI)
Public Since
October 2022 · De-SPAC (MAAQ)
Revenue at Merger
$901 (lifetime)
Products
Epi+Gen CHD · PrecisionCHD
Capital Raised vs. Revenue
$15M+ raised · ~$65K earned
Shareholder Dilution
83% since inception
Key Players
Jonathan Intrater
CEO & Chairman, MAAQ · Managing Director, Ladenburg Thalmann
A serial SPAC sponsor whose two completed de-SPACs have combined to destroy approximately 99% of investor capital. Served simultaneously as MAAQ CEO and managing director at its underwriter Ladenburg Thalmann — a conflict of interest disclosed in the S-4. Previously held board and audit committee roles at GreenVision Acquisition Corp, whose target Helbiz (HLBZ) was delisted from Nasdaq. Named personally as a defendant in a civil fraud lawsuit related to a Ladenburg-led private placement for Digital Broadcast Corporation; the case was dismissed on damages grounds.
⚠ Civil Lawsuit · Two Delisted De-SPACs
Tong Mao
Sole Member, Mana Capital LLC & Juventus LLC · Hong Kong lawyer
A specialist in structuring Chinese capital into U.S. public markets by navigating disclosure requirements. Appears exactly once in CDIO's SEC filing history — disclosing a transfer of 1.565 million shares and 2.5 million warrants to Juventus LLC and unidentified recipients at zero consideration on the day after closing. His two entities together acquired 1.62 million founder shares for $25,000 ($0.015/share). No identifiable successor has filed beneficial ownership reports with the SEC since October 26, 2022.
⚠ Beneficial Ownership Gap · Undisclosed Recipients
309×
More capital raised from stock sales than earned from customers
$3.5M from equity issuance vs $11,270 in revenue
for the nine months ended September 30, 2025
$3.5M from equity issuance vs $11,270 in revenue
for the nine months ended September 30, 2025
CEO Salary vs. Annual Revenue
26.6×
The CEO received a $300,000 annual salary against $11,270 in total nine-month revenue — more than twenty-five times the company's reported earnings for the period.
Dilution Monitor — Soft Catalyst Indicators
C2 — Soft Catalyst
ATM Remaining Capacity
$5.86M
Approx. Market Cap
~$9M
ATM as % of Market Cap
~65%
Estimated Cash Runway
~13 months
Monthly Cash Burn
~$484K
Float Expansion Since IPO
+476%
Fugazi Research — Conclusion
A Company That Sells Equity, Not Diagnostics — and Raises Serious Questions About Who Benefits
▼ Short Position · Zero Value Thesis
Cardio Diagnostics presents itself as an AI-powered precision cardiovascular diagnostics company, but the financial statements, capital structure, and ownership record tell a different story. After raising more than $15 million in equity capital against approximately $65,000 in cumulative revenue, executing a 1-for-30 reverse stock split, and cycling through a CEO who simultaneously ran the underwriter, the company warrants serious scrutiny about its foundational purpose. The identity of those who received 1.565 million shares and 2.5 million warrants on the day after closing — transferred at zero consideration to undisclosed recipients — remains unknown in the public record. Fugazi Research considers the shares completely uninvestable.
Key Risk Factors
🔄 ATM Dilution Overhang
Nearly $5.86M in remaining ATM capacity against a ~$9M market cap represents substantial near-term dilution risk for existing shareholders.
📉 Accelerating Revenue Decline
A 63% year-over-year revenue decline following the loss of a single customer suggests the commercial base is too fragile to support the company's cost structure.
⏳ Cash Runway Pressure
With roughly 13 months of runway at current burn rates, CDIO faces near-certain additional equity issuance or existential liquidity risk absent a dramatic operational reversal.
📋 Unresolved Disclosure Questions
The identity of post-closing share transfer recipients remains unknown in any SEC filing, raising ongoing regulatory risk around beneficial ownership disclosure obligations.
🏛️ Nasdaq Listing Fragility
A prior deficiency notice and a 1-for-30 reverse split executed solely for compliance purposes signal ongoing vulnerability to eventual delisting.
📡 Low-Float Volatility Risk
The 450% price surge on no material news illustrates how thin-float dynamics create transient valuation disconnects — representing sharp downside risk for holders at elevated prices.
Legal Disclaimer
The research, commentary, reports, and other materials published by Fugazi Research LLC ("Fugazi Research," "we," "us," or "our,") are provided solely for informational and educational purposes. Fugazi Research is an independent research publisher and is not registered as an investment adviser, broker-dealer, or commodity trading advisor with the U.S. Securities and Exchange Commission or any other regulatory authority. All content published by Fugazi Research represents our opinions as of the date of publication and is based on publicly available information, independent research, interviews, and analytical judgment. Our opinions are inherently subjective, may be incomplete, and are subject to change at any time without notice. We do not undertake any obligation to update or revise our content to reflect subsequent events, market developments, or new information. Nothing published by Fugazi Research constitutes investment advice, financial advice, legal advice, tax advice, or a recommendation to buy, sell, or hold any security or financial instrument. Fugazi Research, its affiliates, principals, members, employees, consultants, or clients may have positions—long, short, or otherwise—in the securities discussed, and such positions may change at any time for any reason, including risk management, market conditions, or liquidity considerations. Readers should assume that Fugazi Research has a financial interest in the securities discussed. While we believe the information we present is accurate and reliable, it is provided "as is" and "as available," without any representation or warranty, express or implied, as to accuracy, completeness, timeliness, or fitness for any particular purpose. Fugazi Research disclaims any liability for errors, omissions, or losses arising from the use of our content. By accessing or using Fugazi Research's materials, you acknowledge and agree that Fugazi Research shall not be liable for any direct, indirect, incidental, consequential, or other losses arising from reliance on our research or opinions. All content is the intellectual property of Fugazi Research and may not be reproduced, distributed, or shared without prior written consent. This dashboard is published by Activ8 Insights for editorial and informational purposes only and does not constitute investment advice.
Published by Activ8 Insights · Source: Fugazi Research · March 13, 2026